OxLDL plasma levels in patients with Alzheimer's disease

被引:1
|
作者
Grossi, Marina Felipe [1 ]
Gracas Carvalho, Maria das [1 ]
Silveira, Josionne Nicacio [1 ]
Goncalves, Gisele Santos [1 ,2 ]
Gomes, Karina Braga [1 ]
Bicalho, Maria Aparecida [3 ,4 ]
Oliveira Silva, Ieda de Fatima [1 ]
机构
[1] Univ Fed Minas Gerais, Fac Farm, Dept Anal Clin & Toxicol, Belo Horizonte, MG, Brazil
[2] Ctr Univ Newton Paiva, Belo Horizonte, MG, Brazil
[3] Univ Fed Minas Gerais, Hosp Clin, Inst Jenny de Andrade Faria, Belo Horizonte, MG, Brazil
[4] Univ Fed Minas Gerais, Fac Med, Dept Clin Med, Belo Horizonte, MG, Brazil
关键词
Alzheimer's disease; Cholesterol; LDL; BRAZILIAN VERSION; DEMENTIA; VALIDITY; RELIABILITY; ASSOCIATION; CHOLESTEROL; OXIDATION; PROTEIN; RISK;
D O I
10.1590/0004-282X20180012
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Objective: The objective of this study was to characterize the conventional lipid profile, oxLDL levels and ApoE polymorphism in patients with Alzheimer's disease (AD) and in elderly individuals without cognitive impairment. Methods: Eighty elderly individuals were selected and the levels of oxLDL were determined using the ELISA kit, and ApoE gene polymorphism was investigated using polymerase chain reaction-restriction fragment length polymorphism. Results: Significantly reduced levels of oxLDL were observed in patients with AD compared to the control group. A higher frequency of the ApoE epsilon 4 allele was observed in patients with AD compared to controls. No difference was observed for total cholesterol, HDL-C, and LDL-C levels between the two groups, while triglyceride levels were higher in controls compared with patients with AD. Conclusion: The data analyzed together did not reveal significant differences in lipid profiles, including oxLDL levels. However, the importance of lipid changes in the genesis of the disease cannot be ruled out. Nevertheless, the ApoE epsilon 4 allele was significantly more frequent in patients with Alzheimer's dementia in agreement with previous findings in the literature, but this genetic component did not change the levels of oxLDL.
引用
收藏
页码:241 / 246
页数:6
相关论文
共 50 条
  • [31] Increased Levels of Soluble p3-Alcadeinα in Plasma of Patients with Alzheimer's Disease
    Kamogawa, Kenji
    Kohara, Katsuhiko
    Tabara, Yasuharu
    Shinohara, Nako
    Ochi, Masayuki
    Nagai, Tokihisa
    Takita, Rie
    Kawano, Yuji
    Igase, Michiya
    Miki, Tetsuro
    Konno, Tomoko
    Hata, Saori
    Suzuki, Toshiharu
    NEUROLOGY, 2011, 76 (09) : A551 - A551
  • [32] Correlation of plasma homocysteien and folate levels with white matter changes in Alzheimer's disease patients
    Kim, S. G.
    Jung, H. Y.
    Lee, S. Y.
    Shin, E. Y.
    Jung, W. Y.
    Park, J. H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S556 - S556
  • [33] Altered TIMP-3 Levels in the Cerebrospinal Fluid and Plasma of Patients with Alzheimer's Disease
    Park, Jung Hyun
    Cho, Sun-Jung
    Jo, Chulman
    Park, Moon Ho
    Han, Changsu
    Kim, Eun-Joo
    Huh, Gi Yeong
    Koh, Young Ho
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (05):
  • [34] Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease
    Kim, Tae-Suk
    Lim, Hyun-Kook
    Lee, Ji Youl
    Kim, Dai-Jin
    Park, Sanghi
    Lee, Chul
    Lee, Chang-Uk
    NEUROSCIENCE LETTERS, 2008, 436 (02) : 196 - 200
  • [35] Plasma total homocysteine levels as risk factor of cerebrovascular pathology in Alzheimer's disease patients
    Pfeffer, A
    Golebiowski, M
    Wasiak, B
    Styczynska, M
    Gabryelewicz, T
    Czyzewski, K
    Barcikowska, M
    Luczywek, E
    Stepien, K
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S303 - S303
  • [36] Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer's disease
    Schultz, Nina
    Janelidze, Shorena
    Byman, Elin
    Minthon, Lennart
    Nagga, Katarina
    Hansson, Oskar
    Wennstrom, Malin
    PLOS ONE, 2019, 14 (06):
  • [37] Altered plasma cytokine levels in Alzheimer's disease: Correlation with the disease progression
    Motta, M.
    Imbesi, R.
    Di Rosa, M.
    Stivala, F.
    Malaguarnera, L.
    IMMUNOLOGY LETTERS, 2007, 114 (01) : 46 - 51
  • [38] Decreased plasma antioxidants in patients with Alzheimer's disease
    Kim, TS
    Pae, CU
    Yoon, SJ
    Jang, WY
    Lee, NJ
    Kim, JJ
    Lee, SJ
    Lee, C
    Paik, IH
    Lee, CU
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2006, 21 (04) : 344 - 348
  • [39] Plasma Amyloid-β Forms in Alzheimer's Disease and Non-Alzheimer's Disease Patients
    Le Bastard, Nathalie
    Leurs, Judith
    Blomme, Walter
    De Deyn, Peter Paul
    Engelborghs, Sebastiaan
    JOURNAL OF ALZHEIMERS DISEASE, 2010, 21 (01) : 291 - 301
  • [40] Biomonitoring of mycotoxins in the plasma of patients with Alzheimer's disease and Parkinson's disease
    Souques, Martine
    ENVIRONNEMENT RISQUES & SANTE, 2022, 21 (03): : 249 - 250